#NewDrugApproval

F351, a treatment for liver fibrosis derived from chronic hepatitis B, has been designated as a priority review item by China NMPA, with a formal NDA submission planned soon.

Nexera Pharma announced the submission of a manufacturing and marketing authorization application for the dual orexin receptor antagonist daridorexant in South Korea, aiming for approval in 2027.